Email: info@reachlab.health
Email: info@reachlab.health

What Are You Looking For?

Helping detect bowel cancer earlier with a simple blood test

The MOTION Study is testing whether a straightforward blood test can help doctors identify patients who may be at higher risk of bowel cancer. This research could improve the speed and accuracy of cancer diagnosis, helping patients get the care they need sooner.
Learn How the Study Works PARTICIPATE IN MOTION STUDY
shape
shape

Helping detect bowel cancer earlier with a simple blood test

The MOTION Study is testing whether a straightforward blood test can help doctors identify patients who may be at higher risk of bowel cancer. This research could improve the speed and accuracy of cancer diagnosis, helping patients get the care they need sooner.
Learn How the Study Works PARTICIPATE IN MOTION STUDY
shape
shape

Why is this study important?

Major Health Concern

Bowel cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death in the UK.

Major Health Concern

Early Detection Saves Lives

Bowel Cancer is highly treatable and often curable, especially when caught at an early stage.

Early Detection Saves Lives

Patient-friendly tests

A simple blood test could help doctors more accurately determine which patients need urgent investigation.

Patient-friendly tests

Current Pathways & Challenges

Current Process
  • GP referrals via urgent pathways like Two-Week Wait (2WW) or Straight to Test (STT)
  • Rapid access to diagnostic tests like colonoscopy or CT scan
Current Challenges
  • Non-specific symptoms that mimic less serious conditions
  • Ageing population increasing demand
  • Overall rise in patient numbers
  • Limited availability of colonoscopy and CT scans

What is Being Tested?

Progastrin

A hormone precursor that is often elevated in patients with bowel cancer.

Transposable Elements (TEs)

DNA sequences that can move within our genes, potentially disrupting or reversing mutations; linked to cancer development.

Study Flow (At a Glance)

An overview of each step in the study, from consent to sample analysis, supporting advancements in colorectal diagnostics.

feature-shape
feature-shape

Invitation

2WW patients invited to take part

Consent

Consent given during hospital appointment

Blood Sample

A small 20ml blood sample taken

Analysis

Blood sample analysed for biomarkers

Comparison

Results compared with colonoscopy or CT scan

Survey

Optional online survey at the end of 2WW pathway

Study Team

Mohamed Thaha

Chief Investigator

Valentin Butnari

Research Fellow

Eleanor McAlees

Clinical Trials Research Nurse

Deepak Dinkar

Study Manager

Sherif Raouf

Co-Investigator
Partners

Your privacy is our priority

Data Handling

  • Information pseudonymised (study ID, not name)
  • Stored securely on QMUL database (GDPR compliant)
  • Only authorised staff can access records

Sample Handling

  • Stored at QMUL's National Bowel Research Centre
  • Analysed partly in UK, partly at Biodena Care (France)
  • Samples kept for 5 years, then securely destroyed

Results & Publications Snapshot

How results will be used:
  • Findings will help NHS improve prioritisation of cancer checks
  • Published in scientific journals
  • Presented at medical conferences
  • Reports shared with funder LAPResearch UK and patient organisations

Will participants get results?

Yes. During the consent process, participants can choose to receive their individual study results at the end of the trial.

Individual results available

Funding Acknowledgement

LAP Research UK

https://www.lapresearch.org/

Progastrin Manufacturing

https://www.biodenacare.com/